In a significant regulatory development, the U.S. Food and Drug Administration (FDA)recently approved a label change for Depo-Provera, a widely prescribed injectable contraceptive manufactured by Pfizer. The updated warning addresses a potential association between Depo-Provera and meningioma, a type of tumor that forms in the membranes surrounding the brain and spinal cord.
The FDA-approved labeling now states that cases of meningioma have been reported with use of medroxyprogesterone acetate, the active hormone in Depo-Provera, particularly with long-term or repeated exposure. While many meningiomas are considered benign, they can cause serious neurological symptoms depending on their size and location and may require surgery or other medical intervention.
This label change follows years of scientific research and international regulatory action examining the relationship between progestin-based medications and meningioma risk. Other countries had previously required similar warnings before the FDA’s recent decision.
Why This Matters
FDA-mandated warnings are not issued lightly. A label change reflects the agency’s conclusion that available evidence warrants informing physicians and patients of a meaningful safety concern. For many patients, this information was not disclosed during years of Depo-Provera use, despite emerging data suggesting elevated risk with prolonged exposure.
The FDA’s action also comes amid ongoing litigation alleging that patients were not adequately warned about this risk earlier, depriving them of the opportunity to make fully informed decisions about their healthcare.
This warning change will impact that litigation, and should make it easier for injured patients to bring claims against Pfizer regarding their Depo-Provera use.
Questions About Depo-Provera Use?
If you or a loved one:
- Used Depo-Provera for contraception, especially for multiple years, and
- Were later diagnosed with a meningioma or other brain tumor, or experienced unexplained neurological symptoms,